Summit Materials, Inc. (SUM) Is At $26.25 Formed Wedge; Ardsley Advisory Partners Has Raised Adamas Pharmaceuticals (ADMS) Position

Summit Materials, Inc. (NYSE:SUM) Logo

Summit Materials, Inc. (SUM) formed wedge down with $25.46 target or 3.00% below today’s $26.25 share price. Summit Materials, Inc. (SUM) has $3.02 billion valuation. The stock increased 1.74% or $0.45 during the last trading session, reaching $26.25. About 1.92M shares traded or 38.96% up from the average. Summit Materials, Inc. (NYSE:SUM) has risen 4.22% since July 1, 2017 and is uptrending. It has underperformed by 8.35% the S&P500. Some Historical SUM News: 08/05/2018 – Summit Materials 1Q Adj Loss/Shr 55c; 08/05/2018 – Summit Materials 1Q Loss $55.9M; 08/05/2018 – SUMMIT MATERIALS 1Q NET REV. $289.9M, EST. $299.7M; 08/05/2018 – SUMMIT MATERIALS – FOR FULL-YEAR 2018, CO REITERATED CAPEX GUIDANCE OF RANGE OF $210 MLN TO $225 MLN; 23/03/2018 – S&PGR Upgrades Summit Materials LLC To ‘BB’, Outlook Stable; 23/03/2018 – S&P REVISES SUMMIT MATERIALS LLC TO RATING ‘BB’ FROM ‘BB-‘; 17/04/2018 – Summit Materials Debt Risk Falls 4 Levels in Bloomberg Model; 22/03/2018 – lnsteel Industries Announces Addition of Abney S. Boxley, lll to its Board of Directors; 31/05/2018 – Summit Materials at Tour Hosted By SunTrust Today; 08/05/2018 – Summit Materials 1Q Loss/Shr 49c

Ardsley Advisory Partners increased Adamas Pharmaceuticals Inc (ADMS) stake by 41.94% reported in 2018Q1 SEC filing. Ardsley Advisory Partners acquired 65,000 shares as Adamas Pharmaceuticals Inc (ADMS)’s stock rose 13.10%. The Ardsley Advisory Partners holds 220,000 shares with $5.25 million value, up from 155,000 last quarter. Adamas Pharmaceuticals Inc now has $696.95 million valuation. The stock increased 2.30% or $0.58 during the last trading session, reaching $25.83. About 541,945 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 88.75% since July 1, 2017 and is uptrending. It has outperformed by 76.18% the S&P500. Some Historical ADMS News: 19/04/2018 – Adamas: Patients Receiving Gocovri Experienced Long-Term Durability for Up to Two Years; 15/05/2018 – Ghost Tree Capital Buys New 1.2% Position in Adamas Pharma; 03/05/2018 – Adamas Pharma Presenting at Bank of America Conference May 16; 15/03/2018 – ADAMAS REPORTS PHASE 3 DATA OF GOCOVRI IN PARKINSON’S PATIENTS; 10/04/2018 – Adamas Pharma at Deutsche Bank Health Care Conference May 8; 19/04/2018 – ADAMAS PHARMACEUTICALS INC – RESULTS DEMONSTRATED THAT GOCOVRI WAS GENERALLY WELL TOLERATED; 19/04/2018 – Adamas Announces Final Results From Phase 3 Study of GOCOVRI in Parkinson’s Disease Patients With Dyskinesia; 25/04/2018 – USGS: M 4.3 – 58km W of Adamas, Greece; 15/05/2018 – Adamas Pharma Presenting at Bank of America Conference Tomorrow; 15/03/2018 – ADAMAS PHARMACEUTICALS – THE 2 POOLED PHASE 3 STUDIES SHOWED GOCOVRI-TREATED PATIENTS EXPERIENCED 41 PCT FALL IN DYSKINESIA FROM BASELINE AT WEEK 12

More important recent Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) news were published by: Globenewswire.com which released: “Adamas Announces New Employment Inducement Grant” on June 08, 2018, also Nasdaq.com published article titled: “Adamas Presents New Data Analysis Demonstrating that GOCOVRIâ„¢ Reduces Transitions between Dyskinesia and …”, Seekingalpha.com published: “What Does The Rate Hike Mean For Stocks? – Cramer’s Mad Money (6/13/18)” on June 14, 2018. More interesting news about Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was released by: Seekingalpha.com and their article: “Aptinyx IPO: It Collaborated With Allergan, But Shares Are Not Cheap” with publication date: June 27, 2018.

Among 6 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamas Pharmaceuticals had 11 analyst reports since January 23, 2018 according to SRatingsIntel. Leerink Swann initiated it with “Buy” rating and $3100 target in Wednesday, April 4 report. Evercore maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Tuesday, February 20 with “Buy” rating. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has “Buy” rating given on Friday, February 23 by Needham. The company was maintained on Tuesday, February 20 by Mizuho. Mizuho maintained the stock with “Buy” rating in Friday, June 22 report. Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Friday, March 9 with “Buy” rating. The firm has “Buy” rating by Mizuho given on Thursday, April 19. Mizuho maintained the shares of ADMS in report on Tuesday, January 23 with “Buy” rating. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has “Buy” rating given on Tuesday, January 30 by Piper Jaffray. Piper Jaffray maintained it with “Buy” rating and $49.0 target in Thursday, February 22 report.

Ardsley Advisory Partners decreased Deutsche Bank Ag (Call) stake by 175,000 shares to 150,000 valued at $2.10M in 2018Q1. It also reduced Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) stake by 5,000 shares and now owns 106,000 shares. Hi (NYSE:HCLP) was reduced too.

Summit Materials, Inc. (NYSE:SUM) Ratings Chart